Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronac Mamtani

Showing results (61-70 of 198) with videos related to

Pageof 20
Sort By:
Journal of Cancer Research and Clinical Oncology|March 2, 2023
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysisTimothy J Brown, Ronac Mamtani, Phyllis A Gimotty, et al.
Cancer Research and Treatment|December 8, 2015
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder CancerVivek Narayan, Ronac Mamtani, Stephen Keefe, et al.
JAMA Oncology|April 15, 2021
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung CancerLova Sun, Miles Hsu, Roger B Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2025
"Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck CancerMargaret Stalker, Kewen Qu, Roger B Cohen, et al.
JNCI Cancer Spectrum|July 9, 2022
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in MortalityDaniel T Vader, Ravi B Parikh, Haojie Li, et al.
Clinical Genitourinary Cancer|April 30, 2024
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab VedotinEvangelia Vlachou, Ronac Mamtani, Noah M Hahn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2016
Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcomeBen Boursi, Bruce J Giantonio, James D Lewis, et al.
Pharmacoepidemiology and Drug Safety|December 30, 2015
Increasing use of prescription drugs in the United KingdomFrank Zhang, Ronac Mamtani, Frank I Scott, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records databaseFrank I Scott, Ronac Mamtani, Kevin Haynes, et al.
JAMA Network Open|April 14, 2023
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial CancerRonac Mamtani, Hanxi Zhang, Ravi B Parikh, et al.
Pageof 20

Showing results (61-70 of 198) with videos related to

Sort By:
Pageof 20
Journal of Cancer Research and Clinical Oncology|March 2, 2023
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysisTimothy J Brown, Ronac Mamtani, Phyllis A Gimotty, et al.
Cancer Research and Treatment|December 8, 2015
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder CancerVivek Narayan, Ronac Mamtani, Stephen Keefe, et al.
JAMA Oncology|April 15, 2021
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung CancerLova Sun, Miles Hsu, Roger B Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2025
"Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck CancerMargaret Stalker, Kewen Qu, Roger B Cohen, et al.
JNCI Cancer Spectrum|July 9, 2022
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in MortalityDaniel T Vader, Ravi B Parikh, Haojie Li, et al.
Clinical Genitourinary Cancer|April 30, 2024
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab VedotinEvangelia Vlachou, Ronac Mamtani, Noah M Hahn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2016
Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcomeBen Boursi, Bruce J Giantonio, James D Lewis, et al.
Pharmacoepidemiology and Drug Safety|December 30, 2015
Increasing use of prescription drugs in the United KingdomFrank Zhang, Ronac Mamtani, Frank I Scott, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records databaseFrank I Scott, Ronac Mamtani, Kevin Haynes, et al.
JAMA Network Open|April 14, 2023
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial CancerRonac Mamtani, Hanxi Zhang, Ravi B Parikh, et al.
Pageof 20